首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review
【24h】

The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review

机译:在多囊卵巢综合征的管理中使用肌醇异构体:全面审查

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM). We analyzed the available literature with key words PCOS, Myo-inositol, D-chiro-inositol, assisted reproductive technologies and GDM. The most recent literature would suggest that Myo-inositol, D-chiro-inositol and their combination in physiological ratio 40:1 could represent an important therapeutic strategy for the improvement of metabolic, hormonal and reproductive aspects of PCOS. In assisted reproductive technologies, however, myo-inositol and the combined treatment, despite D-chiro-inositol mono-therapy, are able to improve clinical outcomes. Myo-inositol monotherapy results more effective in preventing and treating GDM even if a larger cohort of studies is needed to better clarify these results.
机译:本综述的目的是介绍关于肌醇在多囊卵巢综合征(PCOS)妇女管理中的作用的当前数据以及妊娠期糖尿病(GDM)的预防和治疗。 我们用关键词PCOS,Myo-inositol,D-Chiro-inositol,辅助生殖技术和GDM分析了可用文献。 最近的文献旨在表明,肌醇肌醇,D-Chiro-intositol及其在生理比例中的组合40:1可以代表改善PCOS的代谢,激素和生殖方面的重要治疗策略。 然而,在辅助生殖技术中,尽管D-甲基肌醇单疗法,但肌醇和联合治疗能够改善临床结果。 即使需要更大的研究队列以更好地澄清这些结果,Myo-intositol单药治疗结果也更有效地预防和治疗GDM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号